Frontlight ResearchEarly access
Taking peoplePhase 2
Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis
Key facts
- Who runs it
- London School of Hygiene and Tropical Medicine
- Where
- Indonesia, Malawi, and South Africa3 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 90 people, planned
- Started
- 4 May 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Linezolid (LZD)
- Amoxicillin
- Benzathine Penicillin G
- Record updated
- 22 October 2026
Who can take part
- Age
- 0 days to 7 days
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Infants at risk of congenital syphilis at birth defined as:; an infant born to a mother who tests positive for syphilis in pregnancy using registered and licensed locally-available diagnostic tests for example but not limited to a Treponemal rapid POCT, an RPR or both; AND; the mother is untreated in the current pregnancy defined as:; she tested positive at antenatal care and received no treatment OR ii. she was never tested during antenatal care OR iii. she tested negative at antenatal care and positive on re-testing at delivery; OR c. the mother is inadequately treated in the current pregnancy defined as:; Having received a non-penicillin based treatment regimen; and/or ii. Does not have documentation of 3 doses of IM Benzathine Penicillin, given 7-10 days apart, with the last dose given > 30 days prior to delivery OR b. The mother was adequately treated in the current pregnancy BUT considers herself at risk of re-infection following a midwife delivered explanation of risk (partner treatment, multiple partners etc)
- Infants who are asymptomatic for a diagnosis of congenital syphilis following application of a clinical proforma by the study team (Appendix 1)
- Infants who are less than <= 7 days of life AND with a post-menstrual age (PMA) of 34-42 weeks (Appendix 2)
- Infants who are tolerating enteral feeds, including if they are being administered by an NG tube
Who cannot take part
- 1. The infant's clinical condition at birth or prior to randomisation requires ongoing (> 48 hours) treatment with antibiotics with the potential for anti-treponemal activity i.e. B-lactams, Cephalosporins, Carbapenems
- They have a birthweight <2kg 3. They are nil by mouth. 4. They have a life-limiting congenital anomaly
This trial is currently available in Indonesia, Malawi, and South Africa.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
CARES-1 is a randomised, open-label, phase II pharmacokinetic (PK) and safety study of ambulatory antibiotics for the treatment of neonates with "all-risk" asymptomatic congenital syphilis.
The 3 groups in the trial
- Oral LinezolidTreatment being tested
10 day course of Linezolid twice a day
Treatment: Linezolid (LZD)
- Oral AmoxicillinTreatment being tested
10 day course of Amoxicillin twice a day
Treatment: Amoxicillin
- IM Benzathine penicillinExisting treatment, for comparison
Single IM dose of IM Benzathine penicillin
Treatment: Benzathine Penicillin G
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 October 2026